Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy.

ABSTRACT: Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I-III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the media

SUBMITTER: Heineman DJ 

PROVIDER: S-EPMC5564882 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature